Latest Articles about ALXN

Positive Data on Bayer Candidate - Analyst Blog

Zacks Equity Research — Fri, 24 May 2013 00:29:04 Z

The HealthCare segment of Bayer ( BAYRY ) recently announced positive results from an interim analysis of the phase III PATENT-2 trial on its pipeline candidate riociguat. PATENT-2, the

Alkermes Reports Earnings for Q4 - Analyst Blog

Zacks Equity Research — Thu, 23 May 2013 22:07:01 Z

Alkermes plc 's ( ALKS ) fourth quarter of fiscal 2013 (ended Mar 31, 2013) adjusted earnings (including stock-based compensation expense) of 21 cents per share compared favorably to the

Bayer Files Riociguat in Japan - Analyst Blog

Zacks Equity Research — Wed, 22 May 2013 02:25:07 Z

The HealthCare segment of Bayer ( BAYRY ) recently submitted a regulatory application for its chronic thromboembolic pulmonary hypertension (CTEPH) candidate, riociguat, in Japan. Bayer

Yet Another Acquisition for Bayer - Analyst Blog

Zacks Equity Research — Tue, 21 May 2013 18:29:31 Z

Bayer ( BAYRY ) recently inked a deal to acquire all shares of Germany-based Steigerwald Arzneimittelwerk GmbH. Steigerwald Arzneimittelwerk is a private pharmaceutical company which

Biogen's Hemophilia BLA Accepted - Analyst Blog

Zacks Equity Research — Mon, 20 May 2013 18:25:38 Z

The US Food and Drug Administration (FDA) recently accepted Biogen Idec's ( BIIB ) Biologics License Application (BLA) for its hemophilia A candidate, Eloctate (recombinant factor VIII Fc

Bayer's Xofigo Cleared in the US - Analyst Blog

Zacks Equity Research — Fri, 17 May 2013 02:30:48 Z

Bayer 's ( BAYRY ) HealthCare segment recently received encouraging news as the US Food and Drug Administration (FDA) approved its oncology drug Xofigo (radium 223 dichloride). Xofigo was

Earnings Beat at Alexion, Ups View - Analyst Blog

Zacks Equity Research — Thu, 25 Apr 2013 20:13:11 Z

Alexion Pharmaceuticals Inc. 's ( ALXN ) first quarter 2013 earnings (excluding special items but including stock-based compensation expense) of 57 cents per share beat the Zacks

Omeros' OMS721 Files for Orphan Drug Status - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 01:11:07 Z

Omeros Corporation ( OMER ) recently announced that the company has filed an Application for Orphan Drug Designation with the US Food and Drug Administration (FDA) for its candidate OMS721.

Market Close Report: NASDAQ Composite index closes at 3,239.17 down -28.35 points

NASDAQ.com News — Tue, 02 Apr 2013 00:45:13 Z

Monday's session closes with the NASDAQ Composite Index at 3,239.17. The total shares traded for the NASDAQ was over 1.44 billion. Declining stocks led advancers by 2.72 to 1 ratio. There were

Bad News for Alexion, Shares Down - Analyst Blog

Zacks Equity Research — Tue, 02 Apr 2013 00:07:41 Z

The US Food and Drug Administration (FDA) recently issued a warning letter to Alexion Pharmaceuticals, Inc. ( ALXN ) as the company did not comply with the current Good Manufacturing

Moving Averages Indicate These Sector ETFs Could be Stretched

ETF Professor — Tue, 26 Mar 2013 01:33:37 Z

In a previous examination of some ETFs and their relationship to simple moving averages, we looked at a group of funds that were either below or vulnerable to giving up their 50-day moving

Alexion Pharma Upgraded to Outperform - Analyst Blog

Zacks Equity Research — Fri, 15 Mar 2013 22:48:02 Z

On Mar 14, 2013, we upgraded Alexion Pharmaceuticals Inc. ( ALXN ) to Outperform from Neutral based on the company's strong fourth quarter 2012 results. Moreover, Alexion Pharma has a

Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy

David Moenning — Thu, 14 Mar 2013 20:52:35 Z

SoTM Bull's Eye Report - Today's Most Compelling Buy Thursday, March 14, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the

Market Close Report: NASDAQ Composite index closes at 3,182.03 up 12.29 points

NASDAQ.com News — Tue, 05 Mar 2013 02:45:17 Z

Monday's session closes with the NASDAQ Composite Index at 3,182.03. The total shares traded for the NASDAQ was over 1.69 billion. Advancers stocks led declining by 1.14 to 1 ratio. There were

Market Close Report: NASDAQ Composite index closes at 3,131.49 down -32.92 points

NASDAQ.com News — Fri, 22 Feb 2013 02:45:12 Z

Thursday's session closes with the NASDAQ Composite Index at 3,131.49. The total shares traded for the NASDAQ was over 2.02 billion. Declining stocks led advancers by 2.3 to 1 ratio. There were